Nivolumab Extends Survival for Patients With the Most Common Lung Cancer

Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC). Among patients with advanced disease that worsened after receiving platinum-based chemotherapy, those treated with nivolumab lived on average three months longer than those treated with docetaxel chemotherapy.

Presented at ASCO 2015, Chicago, IL by Professor Luis Paz-Ares, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain

Year of Production:
Running Time:
Color/Sound:

2015
08:28
Color/Sound

Comments are closed.